伊鲁米娜 ILMN

Jacob Thaysen, Ph.D., Career Highlights: Chief Executive Officer, Illumina, Inc. (since 2023), SVP, President of Life Sciences & Applied Markets Group at Agilent Technologies (2018 - 2023); SVP, President of Diagnostics & Genomics Group (2014 - 2018); VP, General Manager, Diagnostics & Genomics (2013 - 2014) and Corporate Vice President, R&D at Dako, a Danish cancer diagnostic company acquired by Agilent in 2012 (2010 - 2013). Of Note: Chair, ALDA (Analytical, Life Science & Diagnostics Association) (since 2023) and Founder and Chief Technology Officer at Cantion, a research and defense application development company (2001). Education: M. Sc. In Physics from the Technical University of Denmark and Ph.D. in Physics from the Technical University of Denmark.

Ankur Dhingra has been appointed Chief Financial Officer of the Company, effective April 15, 2024. Since May 2022, Mr. Dhingra has served as Chief Financial Officer of Summit Therapeutics Inc. (Summit), a biopharmaceutical oncology company from 2022 - 2024. Mr. Dhingra served as Chief Financial Officer at CareDx, a company focused on transplant patient journey, from March 2021 through May 2022. Prior to CareDx, Mr. Dhingra spent 18 years at Agilent Technologies (Agilent) in various finance and business management roles. From January 2019 through March 2021, he was Vice President of Investor Relations and prior to that, Mr. Dhingra served as Group CFO for Agilent's Life Sciences and Applied Markets business. Mr. Dhingra is a qualified Chartered Accountant (India). He served as VP, Investor Relations, Agilent Technologies from 2019 - 2021.

Dr. Steve Barnard, PhD, 1998 - 2015, VP, Chemistry, Illumina, 2015 - 2023, VP and Head of Global Advanced Science, Illumina, 2023 - Present, Chief Technology Officer, Illumina.

Mr. Kevin Carl Pegels, 2023 - Present, Chief People Officer, Illumina; 2010 - 2023 - VP, Human Resources, Illumina and 2006 - 2010 - VP, HR Operations, NVIDIA

Dr. Gottlieb's extensive policy expertise, including his experience as FDA Commissioner from 2017-2019. Career Highlights: Partner, New Enterprise Associates and senior fellow at AEI, a public policy think tank (since 2019), 23rd Commissioner, FDA (2017 - 2019), Various roles in the public and private sectors including serving as Venture Partner at New Enterprise Associates (2007 - 2017), FDA Deputy Commissioner for Medical and Scientific Affairs (2005 - 2007) and Senior Advisor for Medical Technology to the FDA Commissioner (2003 - 2004). Public Board Service: Pfizer, Inc. (since 2019), Tempus AI, Inc. (since 2019) and UnitedHealth Group (since 2025). Non-Public Board Service: Mount Sinai Medical System, Inc. (since 2023), Commanche Biopharma (since 2023), National Resilience, Inc. (since 2020), Xaira Therapeutics (since 2024) and Aetion, Inc (2019 - 2025). Education: B.A. in Economics from Wesleyan University and M.D. from Mount Sinai School of Medicine of New York University. Of Note: Columnist, Wall Street Journal, Contributor to CNBC and CBS Face the Nation and Elected Member of the National Academy of Medicine.

Keith A. Meister, Career Highlights: Founder, Managing Partner and Chief Investment Officer of Corvex Management LP (since 2010), Chief Executive Officer, Principal Executive Officer and Vice Chairman of the Board of Icahn Enterprises L.P. (2003 - 2010) and Senior Managing Director, Icahn Partners LP (2004 - 2010). Public Board Service: MGM Resorts International (since 2019), GeneDx Holdings Corp. (since 2022), Vestis Corporation (since 2024), CM Life Sciences Inc. (2020 - 2021), CM Life Sciences II Inc. (2020 - 2021), CM Life Sciences III Inc. (2021) and Mr. Meister has previously served on the board of directors of numerous other public companies in his career, including Yum! Brands Inc., The Williams Companies, Inc., ADT, Inc., Ralcorp Holdings, Inc. and Motorola, Inc. (now Motorola Solutions, Inc.). Philanthropic Board Service: Harlem Children's Zone (Chairman) and American Museum of Natural History. Education: A.B. in Government from Harvard College

Caroline D. Dorsa, Career Highlights: EVP and CFO, Public Service Enterprise Group, Inc. (2009 - 2015), SVP of Global Human Health, Strategy and Integration, Merck & Co., Inc. (2008 - 2009), SVP and CFO, Gilead Sciences, Inc. (2007 - 2008), EVP and CFO, Avaya, Inc. (2007) and Various financial and operational positions at Merck & Co., Inc. including Vice President and Treasurer (1987 - 2007). Public Board Service: Biogen, Inc. (2010 - Present; Chair 2023 - Present), Duke Energy Corporation (since 2021), Intellia Therapeutics, Inc (2015 - 2023), Goldman Sachs Funds (2016 - 2021) and Public Service Enterprise Group, Inc. (2003 - 2009). Non-Public Board Service: Founder and current board member emeritus, Institute for Advanced Clinical Trials for Children (since 2016) and Junior Achievement of New Jersey (2009 - 2015). Education: B.A. in History from Colgate University and MBA in Finance and Accounting from Columbia University. Of Note: Named Best 50 Women in Business by NJBIZ (2014).

Susan E. Siegel, Career Highlights: Senior Lecturer, MIT Sloan School of Management (since 2019), Chief Innovation Officer of General Electric (GE) and CEO of GE Business Innovations (GE's growth and innovation business), and CEO of GE Ventures (subsumed into Chief Innovation Officer role) (2012 - 2019), General Partner, Mohr Davidow Ventures (2006 - 2012), President and Board Member of Affymetrix, Inc. (1998 - 2006) and Sr. Executive, Amersham Pharmacia Biotech (1990 - 1998), Final Role: President, Hoefer Business & VP, Business Development & Licensing (1996 - 1998). Public Board Service: Nevro Corp. (since 2020), Align Technology, Inc. (since 2017), Pacific Biosciences of California, Inc. (2006 - 2012) and Affymetrix, Inc. (2000 - 2006). Non-Public Board Service: MIT's The Engine (since 2016; Chairman since 2020), Co-Chair, Stanford Medicine Board of Fellows (since 2017), Kaiser Family Foundation (since 2019), Mass General Brigham's Innovation Growth Board (since 2015) and National Venture Capital Association, Board Member (2012 - 2016). Of Note: Lifetime Achievement Award, Global Corporate Venturing (2020) and named to its Powerlist (2015 - 2019), Fortune's 34 Leaders Who are Changing Healthcare (2017), 100 of the Most Influential Women in Silicon Valley, Silicon Valley Business Journal (2006), Fierce Biotech's Top 10 Women in Medical Devices (2015), Henry Crown Fellow, The Aspen Institute, Featured in Multipliers: How the Best Leaders Make Everyone Smarter, Founding representative board member of NIH's National Center for Advancing Translational Sciences and Served on President Obama's Precision Medicine Initiative Working Group, leading to the creation and launch of All of Us. Education: B.S. in Biology from University of Puerto Rico and M.S. in Biochemistry and Molecular Biology from Boston University Medical School.

Scott B. Ullem, Career Highlights: Chief Financial Officer, Edwards Lifesciences (since 2014), Various positions including Chief Financial Officer Bemis Company, Inc. (2008 - 2013) and Managing Director, Co-Head of Diversified Industries Investment Banking at Bank of America (2005 - 2008) Various positions including Managing Director at Goldman Sachs (1989 - 2005). Public Board Service: Berry Global Corp. (2016 - 2024). Non-Public Board Service: egnite, a digital health technology company (since 2021). Of Note: Henry Crown Fellow at the Aspen Institute. Education: B.A. in Political Science from DePauw University and MBA from Harvard Business School.

Philip W. Schiller, Career Highlights: Apple Fellow at Apple, reporting to CEO Tim Cook and leading the App Store and Apple Events (since 2021), Senior Vice President of Worldwide Marketing at Apple, and a member of Apple's executive team responsible for the company's product marketing, developer relations, business marketing, education marketing, international marketing, and App Store programs (2002 - 2021), Vice President of Product Marketing at Macromedia, Inc. (1995 - 1997) and Director of Product Marketing at FirePower Systems, Inc. (1993 - 1995). Non-Public Board Service: Board of Trustees, Bowdoin College (since 2019) and Board of Trustees, Boston College (since 2010). Of Note: Listed in Forbes The World's Most Influential Chief Marketing Officers every year between 2012 and 2020. Education: B.S. in Biology from Boston College.

Anna Richo, Career Highlights: Corporate Senior Vice President, Strategic Advisor to the CEO and General Counsel, Cargill, Inc. (2024), Corporate Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary, Cargill, Inc. (2019 - 2024), EVP and General Counsel, UCB, a publicly traded Belgian biopharmaceutical company (2012 - 2019), Senior Vice President and Chief Compliance Officer, Amgen Inc. (2008 - 2012), Vice President, Law, Amgen Inc. (2003 - 2008) and Chief Litigation Counsel, Associate General Counsel, and Vice President of Law, Baxter Healthcare (1991 - 2003). Public Board Service: Exelon, Inc. (since 2023), Adamas Pharmaceuticals (2020 - 2021) and Cytyc Corporation (1998 - 2003). Non-Public Board Service: Director, Cargill Foundation, Trustee, DePaul University and Director, Children's Minnesota. Education: B.S. in Industrial and Labor Relations from Cornell University and J.D. from DePaul University College of Law.

On June 16, 2026, the Board of Directors of Illumina, Inc. increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately. Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience. He joined Lilly in 2010, following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization. He previously served on the Board of Directors of Myriad Genetics, Inc. Dr. Skovronsky received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania. He completed residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania.

David P. King, Career Highlights: Chair, President & CEO, Laboratory Corporation of America Holdings (LabCorp) (2007 - 2019) and Executive Chair (2019 - 2020), Managing Member, KingMan LLC, provider of strategic consulting services for stakeholders across the healthcare system (since 2021), Operating Partner, Pritzker Private Capital (2020 - 2021), Former CEO, Current Director & Chairman, Fortis Life Sciences (2023 - Present) and Prior to joining LabCorp, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and an Assistant U.S. Attorney for the District of Maryland. Public Board Service: Privia Health Group Inc. (Chair since 2021), Smith & Nephew PLC (since 2025), ZimVie Inc. (Chair 2022 - 2025) and LabCorp (Board 2007 - 2020; Executive Chair 2009 - 2019; Non-Executive Chair 2019 - 2020). Non-Public Board Service: PathGroup (Chair 2022), LGC Limited (Chair since 2023), AMSURG Corp. (Chair since 2023), Novant Health (Since 2021), AMR Clinical (Chair 2021 - 2026), HealthChannels, LLC (Executive Chair 2021 - 2026) and VaxCare, LLC (2021 - 2025).Of Note: Forbes' America's Most Innovative Leaders (2019) and Former Member of the Advisory Board for Duke University's Robert J. Margolis, MD, Center for Health Policy. Education: B.A. in Public and International Affairs from Princeton University and J.D. from University of Pennsylvania Law School.

As interim General Counsel and Secretary(2024 - 2025), Scott Davies has worldwide responsibility for all legal and intellectual property matters and regulatory and government affairs. He also serves as Illumina's code of ethics compliance officer. Prior to his appointment as interim General Counsel and Secretary, Davies served as Illumina's Vice President, Legal - Chief Corporate Counsel and Assistant Secretary (2016 - 2024). Davies joined Illumina in 2009 as its first corporate-focused attorney and has managed all of Illumina's significant corporate legal matters and transactions since that time. While taking on positions of increasing responsibility, Davies developed and led a global corporate and commercial legal team and has worked closely with Illumina's senior executive team and board of directors on a wide range of legal matters across the spectrum of Illumina's global business operations. Prior to joining Illumina, Davies was a corporate transactions (M&A), securities, and finance attorney for 12 years, including 10 years with Gibson, Dunn & Crutcher LLP, a leading international law firm, and two years with Allen & Overy, a leading UK-based global law firm, resident in its London office. Davies received a J.D. from Cornell Law School and a B.A. from Brigham Young University.

Ms. Patricia Leckman, 2006 - 2010, VP, HR Operations, NVIDIA, 2010 - 2023, VP, Human Resources, Illumina, 2023 - Present, Chief People Officer, Illumina.

Mr. Christensen Jakob Wedel, 2024 - Present Chief Strategy and Corporate Development Officer, Illumina; 2023 - 2024 CEO Chief of Staff, Illumina; 2017 - 2023 Partner, EY-Parthenon.

On September 29, 2022 Illumina, Inc. appointed Scott Ericksen as Vice President and Chief Accounting Officer, effective as of October 16, 2022. Mr. Ericksen has served in roles of increasing responsibility with the Company since November 2013, including in his most recent role as International Controller since September 2021 and, prior to that, as EMEA Controller from August 2019 through September 2021, Senior Director, Technical Accounting from September 2018 through August 2019 and Director, Technical Accounting from June 2016 through August 2019. Prior to Illumina, Mr. Ericksen served as Vice President, Director of Corporate Accounting at Science Applications International Corporation, Inc. and as an Audit Manager at Deloitte.